AZ-W-L-GORE-&-ASSOC
27.4.2016 09:07:39 CEST | Business Wire | Press release
W. L. Gore & Associates (Gore) joined with leaders across the vascular and endovascular community in honoring four European physicians as Pioneers in Performance . The biennial award acknowledges exceptional work in the field of vascular and endovascular therapy, including aortic and lower-limb bypass and dialysis access surgery.
Selected by past award recipients in four categories that corresponded with different aspects of clinical collaboration, each winner was selected through popular vote. By submitting for the nominee of their choice on PioneersinPerformance.com , the broader medical community chose to recognize the following 2016 honorees on the evening of Tuesday, April 26 at the Gore MEDICAL MASTERY Learning Center at the Charing Cross International Symposium in London.
Commitment to Ongoing Learning :
- Amman Bolia, MD, Consultant Radiologist, University Hospitals of Leicester NHS Trust, Leicester, UK
Dedication to Sharing Knowledge with Peers and Patients :
- Jean-Baptiste Ricco MD, PhD, Professor of Vascular Surgery, University Hospital of Poitiers, Poitiers, France
Dedication to Creating Consensus within the Medical Community :
- Hans van Overhagen, MD, PhD, EBIR, Department of Radiology, Haga Teaching Hospital, The Hague, The Netherlands
Dedication to Analysis of Clinical Outcomes:
- Martin Malina, MD, PhD, Vascular and Endovascular Surgeon Consultant, Malmo University Hospital, Malmo, Sweden
Dr. Ross Naylor, a past recipient of the award, noted, “The Pioneers in Performance award program offers a unique opportunity for the vascular community to recognize its own. The exemplarily individuals receiving this year’s award encompass the true spirit of innovation. Congratulations to all of this year’s honorees.”
“The Pioneers in Performance program brings together physicians from all corners of the globe to recognize their fellow physicians for their unwavering dedication to advancing vascular and endovascular therapy and minimally invasive treatment options for patients worldwide,” said Ryan Takeuchi, Gore Aortic Business Leader. “We congratulate and thank this year’s honorees and nominees for their part in driving the industry forward and enhancing the patient experience.”
About W. L. Gore & Associates
At Gore Medical, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit GoreMedical@Chempetitive.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160427005357/en/
Contact:
Chempetitive Group for W. L. Gore & Associates
Andrea Vuturo,
(312) 997-2436
GoreMedical@Chempetitive.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom